RS BioTherapeutics

Curated by Signal

Developer of cannabis-based therapeutics for respiratory diseases

Overview

Developer of cannabis-based therapeutics for respiratory diseases. It offers RSBT-001 is a nebulized, semi-synthetic, cannabidiolic acid complex that provides Interleukin response to inflammation and alveolar macrophages to prevent the progression of both acute and chronic pulmonary inflammation related to respiratory diseases.

Key facts

Founded: 2021
Headquarters: Cumberland, United States
Stage: Sign up to view
Industry: Health Technology

Business model

1 product or service: Sign up to view

Contact

Primary office: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

Ki Mobility
Designer, manufacturer, and distributor of manual wheelchairs
Health TechnologyStevens Point, United States
HeartLogic Training Center
Digital remote monitoring workflow management tool for providers
Health TechnologyMarlborough, United States
Ammie
An app offering chatbot enabled healthcare assistance to the patients
Health TechnologyArcadia, United States

About RS BioTherapeutics

What does RS BioTherapeutics do?

Developer of cannabis-based therapeutics for respiratory diseases.

Where is RS BioTherapeutics headquartered?

RS BioTherapeutics is headquartered in Cumberland, United States.

When was RS BioTherapeutics founded?

RS BioTherapeutics was founded in 2021.

Which sector is RS BioTherapeutics in?

RS BioTherapeutics operates in Health Technology.

Who are RS BioTherapeutics's competitors?

Companies similar to RS BioTherapeutics include Ki Mobility, HeartLogic Training Center, and Ammie.